Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019
SUMMARY
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Solid Tumor, Melanoma, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Myelodysplastic Syndrome, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Solid Tumor, Melanoma, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Myelodysplastic Syndrome, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Boston Biomedical Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exisulind - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Hematological and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP
Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes
Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study
Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split
Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth
May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board
Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding “Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis”
Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials
Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.
Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline
Nov 14, 2018: Adoption as a practical realization development type of the cyclic innovation for clinical empowerment by the Japan Agency for Medical Research and Development
Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry
Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA
Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Boston Biomedical Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exisulind - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Hematological and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP
Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes
Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study
Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split
Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth
May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board
Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding “Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis”
Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials
Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.
Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline
Nov 14, 2018: Adoption as a practical realization development type of the cyclic innovation for clinical empowerment by the Japan Agency for Medical Research and Development
Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry
Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA
Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aileron Therapeutics Inc, H2 2019
Pipeline by Boston Biomedical Inc, H2 2019
Pipeline by Circle Pharma Inc, H2 2019
Pipeline by Dicerna Pharmaceuticals Inc, H2 2019
Pipeline by Fog Pharmaceuticals Inc, H2 2019
Pipeline by iBeCa Therapeutics, H2 2019
Pipeline by PRISM Pharma Co Ltd, H2 2019
Pipeline by Propanc Biopharma Inc, H2 2019
Pipeline by Sapience Therapeutics Inc, H2 2019
Pipeline by Venn Therapeutics LLC, H2 2019
Pipeline by WntRx Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aileron Therapeutics Inc, H2 2019
Pipeline by Boston Biomedical Inc, H2 2019
Pipeline by Circle Pharma Inc, H2 2019
Pipeline by Dicerna Pharmaceuticals Inc, H2 2019
Pipeline by Fog Pharmaceuticals Inc, H2 2019
Pipeline by iBeCa Therapeutics, H2 2019
Pipeline by PRISM Pharma Co Ltd, H2 2019
Pipeline by Propanc Biopharma Inc, H2 2019
Pipeline by Sapience Therapeutics Inc, H2 2019
Pipeline by Venn Therapeutics LLC, H2 2019
Pipeline by WntRx Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Aileron Therapeutics Inc
Boston Biomedical Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Aileron Therapeutics Inc
Boston Biomedical Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
